Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145354 | 0.98 | SLC6A4 (0.46) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B | |
| SCHEMBL8747444 | 0.95 | SLC6A4 (0.42) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B | |
| SCHEMBL1898153 | 0.91 | ALDH1A1 (0.45) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B | |
| SCHEMBL4678558 | 0.80 | SMN1; SMN2 (0.39) | ALDH1A1CYP2A6OPRM1HPGDKDM4E | |
| SCHEMBL694701 | 0.79 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1807152 | 0.79 | SLC6A3 (0.44) | SLC6A4SLC6A3ALDH1A1SLC6A2HDAC3 | |
| SCHEMBL2861574 | 0.78 | DRD3 (0.45) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B | |
| SCHEMBL13222499 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B | |
| SCHEMBL21961572 | 0.77 | SLC6A4 (0.50) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B | |
| SCHEMBL21964255 | 0.77 | SLC6A4 (0.50) | SLC6A4SLC6A3GRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5663029-A | DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | CHEN LI (US) | 2004-10-21 | — | — | US | disclosed |
| US-6806365-B2 | ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. | HOFFMANN-LA ROCHER INC. | 2004-10-19 | — | — | US | disclosed |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | CHEN LI (US) | 2003-06-12 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| US-5663029-A | DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | SLC6A4 3517/4885SLC6A3 3413/4885GRIN1 735/4885 |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | VCAM1, ICAM1, SELL | SLC6A4 399/4885SLC6A3 1630/4885GRIN1 1134/4885 |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | VCAM1, ICAM1, CD59 | SLC6A4 470/4885SLC6A3 601/4885GRIN1 1541/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | SLC6A4 3517/4885SLC6A3 3413/4885GRIN1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.